ESMO: Merck’s Keytruda doubles 5-year survival rate for lung cancer patients chelfand Mon, 09/21/2020 – 02:00
ESMO: Roche, after Tecentriq’s ovarian cancer fail, banks hopes on final survival analysis aliu Sun, 09/20/2020 – 07:45
Despite the important advances in research in recent years, the etiopathogenesis of Alzheimer’s disease is still not fully […]
Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant […]
Faced with a novel lethal virus, employers have struggled to implement their legal duty to protect staff from […]
Minal Singh describes her career in dermatology as someone else’s fault. “I completed a two week placement during […]
Data shows a range of responses in different tumours
Investors include SV Health Investors and Cancer Research UK
Detailed results presented at ESMO also show benefit in prostate cancer
Positive opinions include Pacira’s Exparel and two new vaccines from Sanofi